Cargando…

Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level

Hyperprolactinemia is a common side effect of antipsychotic drugs. Although changes of antipsychotic drugs or reduction of their doses can solve this problem, a modification of the treatment regimen can lead to instability in patients. Herein, we followed up a patient with elevated prolactin caused...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhi, Pu, Wang, Yanqiong, Quan, Wei, Su, Yanli, Zhang, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120516/ https://www.ncbi.nlm.nih.gov/pubmed/30214207 http://dx.doi.org/10.2147/NDT.S167129

Ejemplares similares

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
por: Evernden, Christopher, et al.
Publicado: (2021)

Paliperidone Induced Hypoglycemia by Increasing Insulin Secretion
por: Omi, Tsubasa, et al.
Publicado: (2016)

Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs
por: Kucka, Marek, et al.
Publicado: (2015)

Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
por: Mason, Katy, et al.
Publicado: (2021)

Audit on prolactin monitoring for patients on oral risperidone, intramuscular risperidone, and intramuscular paliperidone
por: Bader, Mohamed
Publicado: (2021)

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY
por: Potkin, Steven G., et al.
Publicado: (2017)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such, Pedro, et al.
Publicado: (2021)

Pseudocyesis: A complication of antipsychotic-induced increased prolactin levels and weight gain
por: Grover, Sandeep, et al.
Publicado: (2013)

Aripiprazole-induced priapism
por: Trivedi, Satya K., et al.
Publicado: (2016)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
por: Kirino, Eiji
Publicado: (2017)

Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole
por: Kotorki, Paraskevi, et al.
Publicado: (2010)

Plasmatic Levels and Response to Variable Doses of Monthly Aripiprazole and Three-Month Paliperidone in Patients with Severe Schizophrenia. Treatment Adherence, Effectiveness, Tolerability, and Safety
por: Fernández-Miranda, Juan J, et al.
Publicado: (2023)

Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole
por: Remmerie, Bart, et al.
Publicado: (2016)

Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms?
por: Jen, Ya-Wen, et al.
Publicado: (2020)

Aripiprazole-induced skin rash
por: Nath, Santanu, et al.
Publicado: (2016)

Aripiprazole-induced transient myopia
por: Cumurcu, Tongabay, et al.
Publicado: (2019)

Effect of long-acting injectable paliperidone 3 monthly and aripiprazol 1 monthly on hospitalization rate in a first-episode psychosis
por: Lopez, P. Gil, et al.
Publicado: (2021)

Worsened hypertension control induced by aripiprazole
por: Yasui-Furukori, Norio, et al.
Publicado: (2013)

Aripiprazole-induced obsessive–compulsive symptoms
por: Nafisa, Dilshana, et al.
Publicado: (2022)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
por: Sapin, Christophe, et al.
Publicado: (2016)

Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate
por: Potkin, Steven G., et al.
Publicado: (2016)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
por: Hodgson, Richard E
Publicado: (2019)

S200. COMPARISON BETWEEN LONG-ACTING INJECTABLE ARIPIPRAZOLE VERSUS PALIPERIDONE PALMITATE IN THE TREATMENT OF SCHIZOPHRENIA: SYSTEMATIC REVIEW AND INDIRECT TREATMENT COMPARISON
Publicado: (2020)

Accidental Overdose of Paliperidone Palmitate
por: Ojimba, Chiedozie, et al.
Publicado: (2019)

Severe arrhythmia induced by orally disintegrating aripiprazole tablets (Bosiqing(®)): a case report
por: Shao, Qing, et al.
Publicado: (2015)

Assessment of hospitalizations in schizophrenia patients treated with paliperidone 1-monthly (PP1M), paliperidone 3-monthly (PP3M), aripiprazole once-monthly (AOM) and other oral antipsychotics (OAP) in clinical practice
por: Rojas, L. Gutiérrez, et al.
Publicado: (2021)

Aripiprazole-induced oculogyric crisis (acute dystonia)
por: Bhachech, Jyotik T.
Publicado: (2012)

Aripiprazole-induced Hepatitis: A Case Report
por: Castanheira, Lígia, et al.
Publicado: (2019)

Circulating prolactin level is increased in metabolically healthy obesity
por: Liu, Jia, et al.
Publicado: (2021)

Paliperidone Reversion of Maternal Immune Activation-Induced Changes on Brain Serotonin and Kynurenine Pathways
por: MacDowell, Karina S., et al.
Publicado: (2021)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
por: Demirci, Kadir, et al.
Publicado: (2015)

Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia
por: Singh, Arun, et al.
Publicado: (2018)

Corrigendum: Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
Publicado: (2017)

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study
por: Potkin, Steven G., et al.
Publicado: (2017)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Publicado: (2019)

Paliperidone Palmitate-induced Urinary Incontinence: A Case Report
por: Karslıoǧlu, Ersin Hatice, et al.
Publicado: (2016)

Paliperidone palmitate-induced facial angioedema: A case report
por: Srifuengfung, Maytinee, et al.
Publicado: (2020)

Co-prescription of aripiprazole on prolactin levels in long-term hospitalized chronic schizophrenic patients with co-morbid type 2 diabetes: A retrospective clinical study
por: Liu, Xuebing, et al.
Publicado: (2023)

Aripiprazole-induced transient myopia: A rare entity
por: Praveen Kumar, K V, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_n8mau0id01mbp39fp18h823r1n